FindTrial
Sign In

Tegavivint

DRUG9 trials

Sponsors

Iterion Therapeutics, Ohio State University Comprehensive Cancer Center, Children's Oncology Group, M.D. Anderson Cancer Center, Lapo Alinari

Conditions

Adenomatous Polyposis Coli (APC) Gene MutationAdvanced Hepatocellular CarcinomaCatenin Beta-1 (CTNNB1) Gene MutationColorectal Cancer (CRC)Colorectal CarcinomaDesmoid TumorEndometrial CarcinomaHepatocellular Carcinoma (HCC)

Phase 1

Phase I, Open-label, Non-randomized Study to Evaluate Safety of BC2059
CompletedNCT03459469
Iterion TherapeuticsDesmoid Tumor
Start: 2018-07-15End: 2022-05-01Updated: 2023-03-01
Osimertinib and Tegavivint as First-Line Therapy for the Treatment of Metastatic EGFR-Mutant Non-small Cell Lung Cancer
RecruitingNCT04780568
Ohio State University Comprehensive Cancer CenterMetastatic Lung Non-Small Cell Carcinoma, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8 +1
Start: 2022-01-18End: 2029-07-31Target: 25Updated: 2026-09-15
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
RecruitingNCT04851119
Children's Oncology GroupColorectal Carcinoma, Endometrial Carcinoma, Melanoma +19
Start: 2021-11-08End: 2028-06-30Target: 147Updated: 2026-08-25
Tegavivint for the Treatment of Relapsed or Refractory Leukemia
Active, not recruitingNCT04874480
M.D. Anderson Cancer CenterRecurrent Leukemia, Refractory Leukemia
Start: 2021-09-27End: 2027-02-02Updated: 2026-08-25
Tegavivint for Treating Patients With Relapsed or Refractory Large B-Cell Lymphoma
RecruitingNCT05755087
Lapo AlinariRecurrent Diffuse Large B-Cell Lymphoma Activated B-Cell Type, Recurrent Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements +6
Start: 2023-03-06End: 2028-03-05Target: 18Updated: 2026-02-27
A Study of Tegavivint (BC2059) in Patients With Advanced Hepatocellular Carcinoma
RecruitingNCT05797805
Iterion TherapeuticsAdvanced Hepatocellular Carcinoma
Start: 2023-09-13End: 2026-06-30Target: 178Updated: 2025-07-04
Tegavivint With Gemcitabine in Patients With Relapsed or Refractory Osteosarcoma
RecruitingNCT07144254
Emory UniversityOsteosarcoma in Children, Osteosarcoma Recurrent, Refractory Osteosarcoma +1
Start: 2026-01-22End: 2028-05-01Target: 24Updated: 2026-10-19
Safety and Efficacy of Tegavivint in Patients With Metastatic Colorectal Carcinoma
RecruitingNCT07463599
HonorHealth Research InstituteAdenomatous Polyposis Coli (APC) Gene Mutation, Catenin Beta-1 (CTNNB1) Gene Mutation, Colorectal Cancer (CRC) +1
Start: 2026-02-17End: 2029-07-01Target: 126Updated: 2026-03-11
Study of Tegavivint Plus Zanzalintinib in Patients With Advanced Hepatocellular Carcinoma
Not yet recruitingNCT07878689
University of Texas Southwestern Medical CenterHepatocellular Carcinoma (HCC)
Start: 2026-12-01End: 2029-12-01Target: 36Updated: 2026-10-16

Related Papers

A phase Ib study of osimertinib and tegavivint as first-line therapy in patients with metastatic <i>EGFR</i> -mutated non–small cell lung cancer (NSCLC).
Journal of Clinical Oncology2026-05-28
A phase 1b study of tegavivint, a TBL1 inhibitor, with gemcitabine in patients with relapsed or refractory osteosarcoma (TIGER).
Journal of Clinical Oncology2026-05-28
Tegavivint, a downstream Wnt/β-catenin inhibitor: Dose-finding results from a phase 1/2 trial in advanced hepatocellular carcinoma (aHCC).
Journal of Clinical Oncology2026-05-27
Abstract B135: Activity of Tegavivint in Hepatocellular Carcinoma with Aberrant Wnt/β-catenin Signaling and Evaluation of Biomarker Response
Molecular Cancer Therapeutics2025-10-22
Abstract CT032: Phase 1/2 trial of the TBL1 inhibitor, tegavivint, in advanced hepatocellular carcinoma (aHCC)
Cancer Research2025-04-251 citations
A phase 1/2 study of the TBL1 inhibitor, tegavivint (BC2059), in patients (pts) with advanced hepatocellular carcinoma (aHCC) with β-catenin activating mutations.
Journal of Clinical Oncology2024-06-015 citations
Abstract 4533: Serum protein changes in patients with desmoid tumors responsive to the TBL1 inhibitor, tegavivint
Cancer Research2023-04-04
Abstract CT185: A phase I dose escalation study of a tegavivint (BC2059) a first-in-class TBL1 inhibitor for patients with progressive, unresectable desmoid tumors
Cancer Research2022-06-151 citations
Results of a phase I dose escalation and expansion study of tegavivint (BC2059), a first-in-class TBL1 inhibitor for patients with progressive, unresectable desmoid tumor.
Journal of Clinical Oncology2022-06-0119 citations
The Evaluation of Health-Related Quality of Life Issues Experienced by Patients with Desmoid-Type Fibromatosis (The QUALIFIED Study)—A Protocol for an International Cohort Study
Cancers2021-06-2216 citations